Thursday, January 1, 2009

Pharmaceuticals and Biologicals by Company C-E

Celgene Corporation

Patient Support Coordinator (PSC) Program
Monday–Friday, 8 am–7 pm, EST
Phone: 800.931.8691

Patient Support Coordinator®
This program offers a dedicated central point of contact to assist providers and cancer patients navigate the challenges of reimbursement, provide information about co-pay assistance, and answer general questions about Celgene products and their distribution.

The Patient Support Coordinator assists cancer patients with:

  • Reimbursement assistance, insurance claims, and appeals
  • Medicare Part D prescription drug benefit issues
  • Locating co-pay assistance programs and services
  • Identifying pharmacies that are registered to dispense Celgene products
  • Determining the status of a prescription
  • Inquiries regarding Celgene’s patient assistance program
  • Information regarding Celgene products and their restricted distribution programs (RevAssist® or S.T.E.P.S.®) or appropriate contacts for other questions.
Reimbursement Hotline and Patient Assistance Program

Monday–Friday, 8 am–7 pm, EST
Phone: 866.742.7646

This hotline provides reimbursement assistance for Vidaza® (azacitidine for injectable suspension) and Innohep® (tinzaparin sodium injection). Our team of reimbursement specialists can help address coverage, coding and payment issues as well as answer questions about Medicare, Medicaid, commercial insurers, and managed care. They also can provide information about the Patient Assistance Program, which was established to help patients who otherwise might not have access to our products.

REVLIMID® (lenalidomide)

REVLIMID® is available only under a restricted distribution program called RevAssist®. Healthcare providers and patients must register with RevAssist®. Information about REVLIMID® and the RevAssist® program can be obtained by calling the Celgene Customer Care Center toll-free at 1-888-423-5436.

Cell Therapeutics, Inc.

Reimbursement Support Line
Monday–Friday, 9 am–6 pm, ET
866.298.8433 Option 4

The Reimbursement Support Line is staffed with trained specialists in payer relations, coding and payment issues unique to the Zevalin (ibritumomab tiuxetan) regimen. These specialists will help you understand the various coding options across sites of service, physician’s office and hospital outpatient, and help you complete correct claim forms for submission to insurance companies. In addition, the specialists will help you navigate through the prior authorization process for the Zevalin regimen and verify insurance benefits specific to your patients’ plans. Zevalin, as part of the Zevalin therapeutic regimen, is indicated for the treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients with Rituxan (rituximab) refractory follicular NHL.

Cephalon Oncology

FENTORA Patient Assistance Program
Monday–Friday, 9 am–8 pm, EST
Hotline: 1.877.4FENTORA (1.877.433.6867)
Fax: 1.866.495.0657

Eligibility: Patients who do not have prescription drug coverage could be eligible for the FENTORA® Patient Assistance Program. The patient must not be eligible for public and private insurance reimbursement (including Medicare Part D), and must meet certain income restrictions and U.S. residency requirements.

Cephalon Oncology Reimbursement Expertise™ (CORE)
Monday–Friday, 9am–6pm, EST

Cephalon Oncology's reimbursement support program, CORE or Cephalon Oncology Reimbursement Expertise™, supports Cephalon Oncology’s product TRISENOX® (arsenic trioxide). Assistance from CORE can be accessed by calling toll free at 1-866-261-7730 or by using the CORE website found at

CORE services are provided to both healthcare professionals and patients. For oncology practices, CORE can provide benefit verifications, coding and claims support, letter of medical necessity templates, assistance in locating relevant medical literature, access to the Cephalon Oncology Patient Assistance Program and appeals support.

Chiron Biopharmaceuticals Reimbursement Service
Monday–Friday, 8 am-5 pm, PST
After hours, leave a message.

The Chiron Reimbursement Service provides reimbursement support for Chiron BioPharmaceuticals' products: Proleukin® (aldesleukin for injection), a recombinant interleukin-2 (rIL-2), which is approved for metastatic renal cell carcinoma and metastatic melanoma, and DepoCyt (cytarabine liposome injection), encapsulated cytarabine approved for the intrathecal treatment of lymphomatous meningitis.

The Chiron Reimbursement Service reimbursement consultants help to minimize claims processing delays and provide information about coding, prior authorization procedures, patient coverage status, and reimbursement amounts and limitations. The reimbursement specialists also determine the status of and reasons for denied claims and assist with filing appeals for denied claims.

Cytogen Corporation

Cytogen Reimbursement Hotline
Monday–Friday, 8:30 am–4:30 pm, ET

Reimbursement specialists are available to assist physicians and institutions with billing, coding, and reimbursement questions pertaining to public payers and private insurers. ProstaScint® is a monoclonal antibody-based diagnostic imaging agent for use in two clinical settings: 1) newly diagnosed patients with biopsy-proven prostate cancer thought to be clinically localized after standard diagnostic evaluation and who are at high risk for pelvic lymph node metastases and 2) post-prostatectomy patients with a rising prostate-specific antigen (PSA) and a negative or equivocal standard metastatic evaluation in whom there is a high clinical suspicion of occult metastatic disease.

CARE OM is a web-based education and support center for patients and caregivers seeking to learn more about oral mucositis (OM) and Caphosol®, an advanced electrolyte solution indicated in the U.S. as an adjunct to standard oral care in treating OM caused by radiation or high-dose chemotherapy. Caphosol, a prescription medical device, is also indicated for dryness of the mouth or throat (hyposalivation, xerostomia), regardless of the cause or whether the conditions are temporary or permanent. In addition to oral mucositis educational material and support information, visitors to CARE OM can also download an OM brochure or request a free brochure about OM by mail.

Eli Lilly

Lilly PatientOne
Monday–Friday, 9 am–7 pm EST
1.866.472.8663, option 1 (1.866.4PatOne, option 1)

Lilly PatientOne is the Lilly oncology program that addresses financial, access, and claim issues for patients who are candidates for Alimta (pemetrexed for injection) and/or Gemzar (gemcitabine HCL for injection).

Among the many services are: reliable, individualized treatment support and patient assistance, including insurance verification and claim submission assistance; information about payment methodologies and allowables and drug information and coding; and claim appeals, a full, start-to-finish commitment.

No comments:

Post a Comment